TCGA's Ovarian Cancer Study Points to Range of PGx Strategies, Potential Role for PARP Inhibitors

The TCGA team identified 68 genes that could be targeted by existing drugs or experimental compounds, and singled out PARP inhibitors as a drug class with particular potential. The study also provides a potential basis for subtype-based diagnostics to stratify patients according to their cancer's genomic variation.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.